tailieunhanh - Rationale and design of ON-TRK: A novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

Tropomyosin receptor kinase (TRK) fusion proteins resulting from neurotrophic tyrosine receptor kinase (NTRK) gene fusions are rare primary oncogenic drivers in a wide array of tumors. Larotrectinib is a first-in-class, highly selective, central nervous system-active TRK inhibitor approved by the US Food and Drug Administration (FDA), European Medicines Agency (EMA), and over 40 countries for the treatment of TRK fusion solid tumors in adult and pediatric patients. |

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN